Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Proteins with expanded polyglutamine repeats cause Huntington's disease and other neurodegenerative diseases. Transcriptional dysregulation and loss of function of transcriptional co-activator proteins have been implicated in the pathogenesis of these diseases. Huntington's disease is caused by expansion of a repeated sequence of the amino acid glutamine in the abnormal protein huntingtin (Htt). Here we show that the polyglutamine-containing domain of Htt, Htt exon 1 protein (Httex1p), directly binds the acetyltransferase domains of two distinct proteins: CREB-binding protein (CBP) and p300/CBP-associated factor (P/CAF). In cell-free assays, Httex1p also inhibits the acetyltransferase activity of at least three enzymes: p300, P/CAF and CBP. Expression of Httex1p in cultured cells reduces the level of the acetylated histones H3 and H4, and this reduction can be reversed by administering inhibitors of histone deacetylase (HDAC). In vivo, HDAC inhibitors arrest ongoing progressive neuronal degeneration induced by polyglutamine repeat expansion, and they reduce lethality in two Drosophila models of polyglutamine disease. These findings raise the possibility that therapy with HDAC inhibitors may slow or prevent the progressive neurodegeneration seen in Huntington's disease and other polyglutamine-repeat diseases, even after the onset of symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The progression of neurodegeneration is slowed by treatment with deacetylase inhibitors, further emphasizing the impor- tance of a controlled balance of protein acetylation and deacetylation in cellular functions in diverse tissues (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
In the citing paper
“A recent report showed that neurodegeneration triggered by expression of the polyglutamine-containing protein Httex1p involves inhibition of CBP/p300- and PCAF-AT activities (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
Citations
Cites
Targeted gene expression as a means of altering cell fates and generating dominant phenotypes
Brand, A. H., & Perrimon, N. (1993) · Development · doi:10.1242/dev.118.2.401 · Cited by 9,612
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595 · cited 1×
“We found that even normal repeat Htt can bind to and inhibit acetyltransferase activity ( Figs 1 and 2 ), so why is pathology associated with only expanded repeat Htt? Mutant Htt can be proteolytically processed; the pathogenic fragment localizes to the nucleus, where it is capable of inhibiting acetyltransferase acti…”
BackgroundA p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479 · cited 1×
“, pGST–P/CAF-AT domain (encoding amino acids 87–768), and pcDNA3 containing the cDNA for P/CA”
MethodGlutamine Repeats and Neurodegeneration
Zoghbi, H. Y., & Orr, H. T. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.217 · Cited by 1,309 · cited 1×
“The aetiology of several other neurodegenerative diseases, including spinocerebellar ataxia I and Kennedy's disease, also involves expansion of a polyglutamine repea”
BackgroundHistone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Nucifora, F. C., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V. L., et al. (2001) · Science · doi:10.1126/science.1056784 · Cited by 1,094
Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,062 · cited 1×
“We previously found that a fragment of mutant Htt interacts directly with CBP, which contains an acetyltransferase domain and is a co-activator of numerous promoter”
BackgroundSelf-citationLuo, L., Liao, Y. J., Jan, L. Y., & Jan, Y. N. (1994) · Genes & Development · doi:10.1101/gad.8.15.1787 · Cited by 983
Cited by
Items 401–500 of 1,000
Epigenetics of Huntington’s Disease
Bassi, S., Tripathi, T., Monziani, A., Leva, F. D., & Biagioli, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53889-1_15 · Cited by 72
The Pleiotropic Face of CREB Family Transcription Factors
Chowdhury, M. A. R., An, J., & Jeong, S. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.2193 · Cited by 73
“Also, it has been recommended that mutant Htt expression may exert an impact on histone acetyltransferases (HATs) like CBP to decrease histone acetylation levels, which is associated with polyQ toxicity (Steffan et al., 2001).”
Colodner, K. J., & Feany, M. B. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2491-10.2010 · Cited by 68
Contribution of Neuroepigenetics to Huntington’s Disease
Francelle, L., Lotz, C., Outeiro, T. F., Brouillet, E., & Mérienne, K. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00017 · Cited by 78
“Major transcriptional changes have been reported in the brains of HD patients (Hodges et al., 2006).”
BackgroundInfluentialYamanaka, K., Okubo, Y., Suzaki, T., & Ogura, T. (2003) · Journal of Structural Biology · doi:10.1016/j.jsb.2003.11.017 · Cited by 71
Can flies help humans treat neurodegenerative diseases?
Marsh, J., & Thompson, L. M. (2004) · BioEssays · doi:10.1002/bies.20029 · Cited by 81
Self-citationPharmacology of epigenetics in brain disorders
Narayan, P., & Dragunow, M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00526.x · Cited by 67
“They further demonstrated that HDAC inhibition prevented polyQ-induced toxicity and neurodegeneration (Steffan et al., 2001), and proposed a novel target for HD therapy.”
BackgroundThe role of HDAC3 and its inhibitors in regulation of oxidative stress and chronic diseases
He, R., Liu, B., Geng, B., Li, N., & Geng, Q. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01399-w · Cited by 75
“HDACs was fi rst found to play an important role in neurodegenerative disease in a study in 2001, which indicated that pharmacological inhibition of HDACs can suppress polyglutamine-dependent neurotoxicity in Drosophila [138].”
Neuroprotective potential of CB1receptor agonists in anin vitromodel of Huntington's disease
Scotter, E. L., Goodfellow, C. E., Graham, E. S., Dragunow, M., & Glass, M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00773.x · Cited by 68
“Steffan et al. (2001) have also shown that soluble, truncated, wild-type huntingtin confers toxic properties, enhancing interaction with histone acetyl transferases and dysregulating gene transcription.”
BackgroundHuntingtin’s Function in Axonal Transport Is Conserved in Drosophila melanogaster
Zala, D., Hinckelmann, M.-V., & Saudou, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060162 · Cited by 67
Kim, M.-O., Chawla, P., Overland, R. P., Xia, E., Sadri‐Vakili, G., & Cha, J.-H. J. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.5667-07.2008 · Cited by 73
Uo, T., Veenstra, T. D., & Morrison, R. S. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.6186-08.2009 · Cited by 70
Benn, C. L., Butler, R., Mariner, L., Nixon, J., Moffitt, H., Mielcarek, M., Woodman, B., & Bates, G. P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005747 · Cited by 66
“therapeutic potential in HD models [20–28], at least partly through increasing the association of acetylated histones with down-regulated genes and correcting mRNA abnormalities [29].”
BackgroundEarly and Late Events Induced by PolyQ-expanded Proteins
Bertoni, A., Giuliano, P., Galgani, M., Rotoli, D., Ulianich, L., Adornetto, A., Santillo, M. R., Porcellini, A., & Avvedimento, V. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.156521 · Cited by 66
Kumar, A., Singh, P. K., Parihar, R., Dwivedi, V., Lakhotia, S. C., & Ganesh, S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.553321 · Cited by 71
“Azaserine Feeding Reduces Mutant Huntingtin Aggregation in the Larval Eye Discs of Drosophila—Having found that azaserine treatment reduces the aggregates of mutant huntingtin in the mammalian cell line, we next tested whether a similar effect could also be seen in vivo, for which we used the fly model of Huntington d…”
BackgroundMethodParker, J. A., Metzler, M., Georgiou, J., Mage, M., Roder, J. C., Rose, A. M., Hayden, M. R., & Néri, C. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1941-07.2007 · Cited by 63
Regulation of gene expression in the nervous system
Ooi, L., & Wood, I. C. (2008) · Biochemical Journal · doi:10.1042/bj20080963 · Cited by 69
Live axonal transport disruption by mutant huntingtin fragments in Drosophila motor neuron axons
Sinadinos, C., Burbidge-King, T., Soh, D., Thompson, L. M., Marsh, J., Wyttenbach, A., & Mudher, A. K. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.012 · Cited by 75
“Available online on ScienceDirect (www.scienced 0969-9961/$ – see front matter © 2009 Elsevier Inc. Al doi:10.1016/j.nbd.2009.02.012 a b s t r a c t a r t i c l e i n f o”
BackgroundInfluentialSelf-citationHistone H3 phosphoacetylation is critical for heroin-induced place preference
Sheng, J., Lv, Z. G., Wang, L., Zhou, Y., & Hui, B. (2011) · Neuroreport · doi:10.1097/wnr.0b013e328348e6aa · Cited by 68
Aron, R., Pellegrini, P., Green, E. W., Maddison, D. C., Opoku-Nsiah, K., Oliveira, A. O., Wong, J. S., Daub, A. C., Giorgini, F., Muchowski, P. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05653-z · Cited by 67
Atoki, A. V., Aja, P. M., Shinkafi, T. S., Ondari, E. N., Adeniyi, I. A., Fasogbon, I. V., Dangana, R. S., Shehu, U. U., & Akin-Adewumi, A. (2024) · Fly · doi:10.1080/19336934.2024.2420453 · Cited by 90
The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease
Gil‐Mohapel, J., & Rego, A. C. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.001 · Cited by 69
“deacetylases (HDACs) might be used to ameliorate these transcriptional changes (Steffan et al., 2001).”
BackgroundMoumné, L., Campbell, K., Howland, D., Ouyang, Y., & Bates, G. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031080 · Cited by 63
“They were first shown to be protective in a Drosophila melanogaster model [25] and following on from the demonstration that SAHA, a potent HDAC”
BackgroundNucleolar dysfunction in Huntington's disease
Lee, J.-H., Hwang, Y. J., Ryu, H., Kowall, N. W., & Ryu, H. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.017 · Cited by 75
Siebzehnrübl, F. A., Raber, K. A., Urbach, Y. K., Schulze-Krebs, A., Canneva, F., Moceri, S., Habermeyer, J., Achoui, D., Gupta, B., Steindler, D. A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807962115 · Cited by 63
Butler, D. C., Mclear, J., & Messer, A. (2011) · Progress in neurobiology · doi:10.1016/j.pneurobio.2011.11.004 · Cited by 59
Transgenic animal models for study of the pathogenesis of Huntington’s disease and therapy
Li, X.-J., Chang, R., Liu, X., & Li, S. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s58470 · Cited by 62
Biermann, J., Boyle, J., Pielen, A., & Lagrèze, W. A. (2011) · PubMed Central · Cited by 69
Li, Y., & Alam, H. B. (2011) · BioMed Research International · doi:10.1155/2011/523481 · Cited by 66
“A number of preclinical studies have demonstrated that HDACI can improve survival in degenerative diseases, prevent brain from various insults, attenuate the e ff ects of aging, and increase life span [23, 43–45].”
BackgroundAyyadevara, S., Balasubramaniam, M., Kakraba, S., Alla, R., Mehta, J. L., & Reis, R. J. S. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6978 · Cited by 64
“In a Drosophila model of Huntington’s disease, ‘‘histone deacetylase inhibitors’’ were found to relieve neuronal degeneration induced by polyglutamate expansion (68).”
Transcriptional alterations and chromatin remodeling in polyglutamine diseases
Helmlinger, D., Tora, L., & Devys, D. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.07.010 · Cited by 70
The Role of H3K4me3 in Transcriptional Regulation Is Altered in Huntington’s Disease
Dong, X., Tsuji, J., Labadorf, A. T., Roussos, P., Chen, J., Myers, R. H., Akbarian, S., & Weng, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144398 · Cited by 75
Ganai, S. A., Banday, S., Farooq, Z., & Altaf, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.001 · Cited by 61
Zhang, S., Sakuma, M., Deora, G. S., Levy, C. W., Klausing, A., Breda, C., Read, K. D., Edlin, C. D., Ross, B. P., Wright Muelas, M., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0520-5 · Cited by 59
Inhibitors of metabolism rescue cell death in Huntington's disease models
Varma, H., Cheng, R., Voisine, C., Hart, A. C., & Stockwell, B. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704482104 · Cited by 61
SUMOylation substrates in neuronal intranuclear inclusion disease
Takahashi‐Fujigasaki, J., Arai, K., Funata, N., & Fujigasaki, H. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00705.x · Cited by 61
Sheeba, V., Fogle, K. J., & Holmes, T. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011628 · Cited by 60
“PolyQ protein expression has been shown previously to cause neurodegeneration and functional loss in photoreceptors and other Drosophila neurons [37,39,58].”
BackgroundKearney, M., Cooper, P. R., Smith, A. J., & Duncan, H. F. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00311 · Cited by 72
Neuronal intranuclear inclusions and neuropil aggregates in HdhCAG(150) knockin mice
Tallaksen‐Greene, S. J., Crouse, A. B., Hunter, J. M., Detloff, P. J., & Albin, R. L. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.10.037 · Cited by 70
The use of transgenic and knock-in mice to study Huntington’s disease
Hickey, M. A., & Chesselet, M.-F. (2003) · Cytogenetic and Genome Research · doi:10.1159/000072863 · Cited by 69
“In view of these observations, treatments aimed at preventing transcription disruption are currently being developed, including treatment with histone deacetylase inhibitors (Hughes et al., 2001; Steffan et al., 2001).”
BackgroundDFT-based ranking of zinc-binding groups in histone deacetylase inhibitors
Vanommeslaeghe, K., Loverix, S., Geerlings, P., & Tourwé, D. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.06.009 · Cited by 60
Neurodegeneration by polyglutamine Atrophin is not rescued by induction of autophagy
Nisoli, I., Chauvin, J., Napoletano, F., Calamita, P., Zanin, V., Fanto, M., & Charroux, B. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.31 · Cited by 63
Chromosomal profiles of gene expression in Huntington's disease
Anderson, A. N., Roncaroli, F., Hodges, A., Deprez, M., & Turkheimer, F. E. (2008) · Brain · doi:10.1093/brain/awm312 · Cited by 59
“Recent studies in HD models have also shown that mutated huntingtin in erferes with the activity of histone acetyltransferase, suggesting that abnormal activity of this enzyme might be a cause of transcriptional dysregulation in HD (Steffan et al., 2001; Sadri-Vakili and Cha, 2006).”
BackgroundGenetic and environmental factors in the pathogenesis of Huntington’s disease
van Dellen, A., & Hannan, A. J. (2004) · Neurogenetics · doi:10.1007/s10048-003-0169-5 · Cited by 61
Popiel, H. A., Nagai, Y., Fujikake, N., & Toda, T. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300045 · Cited by 59
Acetylation of histone deacetylase 6 by p300 attenuates its deacetylase activity
Han, Y., Jeong, H. M., Jin, Y.-H., Kim, Y.-J., Jeong, H. G., Yeo, C., & Lee, K.-Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.03.147 · Cited by 61
Schulte, J., Sepp, K. J., Wu, C., Hong, P., & Littleton, J. T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023841 · Cited by 64
“Drosophila models of neurodegenerative disease have been a powerful tool for understanding mechanisms of neurodegeneration for more than a decade, and have more recently been applied directly to drug discovery as well [67–74].”
MethodNitric Oxide-mediated epigenetic mechanisms in developing neurons
Nott, A., & Riccio, A. (2009) · Cell Cycle · doi:10.4161/cc.8.5.7805 · Cited by 64
Hinwood, M., Tynan, R. J., Day, T. A., & Walker, F. R. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhq080 · Cited by 58
“However, the antibody has been validated for use in western blot procedures both by the manufacturer and in previous studies (Steffan et al. 2001; Kumar et al. 2005; Renthal et al. 2007; Covington et al. 2009; Perisic et al. 2010) and in all instances produces a single band at ~17 kDa.”
MethodGuo, Z., Zhang, Z., Wang, Q., Zhang, J., Wang, L., Zhang, Q., Li, H., & Wu, S. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.11.003 · Cited by 65
“Histone hypoacetylation has been found in the initiation of carcinogenesis and other diseases (Sonia and Richard,1999; McCampbell et al., 2001; Steffan et al., 2001).”
BackgroundEpigenetics in Neurodegenerative Diseases: The Role of Histone Deacetylases
Sharma, S., Sarathlal, K. C., & Taliyan, R. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666181004155136 · Cited by 62
Iijima, K., & Iijima‐Ando, K. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15402 · Cited by 73
“Several fly neurodegenerative models have successfully showed the involvementof transcriptional dysregulation in polyglutamine-repeat diseases [142], molecular chaperones in polyglutamine-repeat diseases and Parkinson’s disease [3,161], and oxidative stress in tauopathies [28].”
Benn, C., Fox, H., & Bates, G. P. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-17 · Cited by 68
“Taken together, it is critical that we can reliably measure Bdnf levels, either when directly attempting to modulate Bdnf expression; or for use as a biomarker in the context of other disease-modifying therapies, particularly those aimed at correcting gene expression deficits, such as histone deacetylase inhibitors [2…”
BackgroundDisruption of the epigenetic code: An emerging mechanism in mental retardation
van Bokhoven, H., & Kramer, J. M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.03.010 · Cited by 55
Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington’s Disease
Paldino, E., Balducci, C., Vitola, P. L., Artioli, L., D’Angelo, V., Giampà, C., Artuso, V., Forloni, G., & Fusco, F. R. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01847-8 · Cited by 56
Sang, T.-K., Li, C., Liu, W., Rodriguez, A., Abrams, J. M., Zipursky, S. L., & Jackson, G. R. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi032 · Cited by 56
“Similar to the approaches used to effect Q108 expression, UAS-huntingtin-exon1-Q93 ( 57 ) and UAS-ataxin- 1-Q82 (58,59) transgenes were expressed using GMR- and Rh1-GAL4 drivers to generate early- and late-onset neurodegeneration, respectively.”
Self-citationMechanisms of transcriptional dysregulation in Huntington's disease
Luthi‐Carter, R., & Cha, J.-H. J. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00059-8 · Cited by 60
“p53-activated Reporter assay of native p21 WAF1/CIP1 promoter [ 61 ] No change with N-terminal fragment of wt htt,”
BackgroundMethodInfluentialThomas, E. (2014) · Pharmaceuticals · doi:10.3390/ph7060634 · Cited by 55
“cause both up- and down-regulation of gene expression patterns, with little predictive value [60,92,113].”
BackgroundBardai, F. H., Verma, P., Smith, C., Rawat, V., Wang, L., & D’Mello, S. R. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5831-12.2013 · Cited by 59
“…with the idea that liberation of HDAC3 from Htt is a key event in neurotoxicity by mut-Htt is the finding that the level of interaction is reduced in the striatum of symptomatic R6/2 mice but not tional dysregulation has been implicated in the pathogenesis of HD (Cha, 2000; Steffan et al., 2001).”
BackgroundHistone acetylation in neuronal (dys)function
Bonnaud, E. M., Suberbielle, E., & Malnou, C. E. (2016) · BioMolecular Concepts · doi:10.1515/bmc-2016-0002 · Cited by 61
Hallam, T. M., & Bourtchouladze, R. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5555-8 · Cited by 69
CREB family transcription factors inhibit neuronal suicide
Dawson, T. M., & Ginty, D. D. (2002) · Nature Medicine · doi:10.1038/nm0502-450 · Cited by 62
The role of genetics in the establishment and maintenance of the epigenome
Huidobro, C., Fernández, A. F., & Fraga, M. F. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1296-2 · Cited by 64
Small molecule modulators of chromatin remodeling: from neurodevelopment to neurodegeneration
Jiang, D., Li, T., Guo, C., Tang, T.-S., & Liu, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00953-4 · Cited by 54
Transcriptional dysregulation in Huntington’s disease: The role of histone deacetylases
Sharma, S., & Taliyan, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.08.002 · Cited by 61
Lee, J.-H., Hwang, Y. J., Boo, J. H., Han, D. K., Kwon, O. K., Todorova, K., Kowall, N. W., Kim, Y. K., & Ryu, H. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.38 · Cited by 59
Thomas, E. A. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8067-y · Cited by 55
Lin, T. K., Chen, H., Koustova, E., Sailhamer, E. A., Li, Y., Shults, C., Liu, B., Rhee, P., Kirkpatrick, J. R., & Alam, H. B. (2007) · Surgery · doi:10.1016/j.surg.2007.01.014 · Cited by 55
Arango-Lievano, M., Holbert, S., Zala, D., Brouillet, E., Pearson, J. L., Régulier, E., Thakur, A. K., Aebischer, P., Wetzel, R. B., Déglon, N., et al. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.5409-05.2006 · Cited by 61
“…regulation of transcription is central to neuronal cell death in HD, a mechanism that may be notably pertinent to cell-autonomous processes (Steffan et al., 2001; Dunah et al., 2002; Jiang et al., 2003; Marcora et al., 2003; Sugars and Rubinsztein, 2003; Zuccato et al., 2003; Gu et al.,…”
BackgroundPathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy
Adachi, H., Waza, M., Katsuno, M., Tanaka, F., Doyu, M., & Sobue, G. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00830.x · Cited by 56
“histone acetylation and a subsequent restoration of gene transcription, HDAC inhibitors have been considered to be of therapeutic benefit in polyglutamine diseases (Steffan et al. 2001).”
BackgroundNeuroprotective Effects of Psychotropic Drugs in Huntington’s Disease
Lauterbach, E. C. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141122558 · Cited by 52
“Chronic lithium administration (rearing in the presence of 4.2 mM lithium) reduced optic photoreceptor neuronal degeneration in the gmr-httQ120 HD Drosophila model expressing the first 171 residues of mutant Htt with 120 repeats, and combining lithium with the mTOR inhibitor rapamycin produced still greater neuroprote…”
BackgroundInfluentialMeng, J., Li, Y., Camarillo, C., Yao, Y., Zhang, Y., Xu, C., & Jiang, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085570 · Cited by 59
“This result supports the fact that the available pharmaceutical therapies such as an acetylcholinesterase inhibitor and glutamate receptor antagonist can only ameliorate cognition of AD patients but fail to reverse the AD pathology [40]; while, the HDAC inhibitor, which affects transcriptional activity, is able to enh…”
BackgroundResultLin, T. K., Alam, H. B., Chen, H., Britten-Webb, J., Rhee, P., Kirkpatrick, J. R., & Koustova, E. (2006) · Surgery · doi:10.1016/j.surg.2005.08.022 · Cited by 53
Zheng, Z., Zhou, Y., Ye, L., Lu, Q., Zhang, K., Zhang, J., Xie, L., Wu, Y., Xu, K., Zhang, H., et al. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113138 · Cited by 54
Roze, E. F., Bonnet, C., Bétuing, S., & Caboche, J. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6448-9_5 · Cited by 60
Yildirim, F., Ji, S., Kronenberg, G., Barco, Á., Olivares, R., Benito, E., Dirnagl, U., Gertz, K. R., Endres, M., Harms, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095465 · Cited by 56
“hemorrhage and cerebral ischemia [5,6,7,8,9,10,11].”
What's wrong with epigenetics in Huntington's disease?
Valor, L. M., & Guiretti, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.10.025 · Cited by 61
“…hypoacetylation and reduced CBP-dependent transcription of polyQ-expressing systems are reversed by CBP overexpression (McCampbell et al., 2000; Steffan et al., 2001; Taylor et al., 2003; Jiang et al., 2006), whereas a 50% reduction of CBP expression exacerbates neurodegeneration in a…”
InfluentialSirtuins: double players in Huntington's disease
Naia, L., & Rego, A. C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.07.003 · Cited by 57
Striatal specificity of gene expression dysregulation in Huntington's disease
Thomas, E. A. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.21046 · Cited by 52
“Furthermore, it has been reported that htt can bind histone acetyltransferase domains of CBP and p300/CBP-associated factor (Steffan et al., 2001).”
BackgroundDrosophila Models of Proteinopathies: the Little Fly that Could
Rincón-Limas, D. E., Jensen, K., & Fernández-Fúnez, P. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799315894 · Cited by 54
“Since manipulation of these Htt transgenes was restricted to the fly eye, a subsequent model expressing a mutant N-terminal fragment (Htt-ex1) capitalized on the flexibility of the UAS/Gal4 system [73].”
BackgroundPharmaceutical, cellular and genetic therapies for Huntington's disease
Handley, O., Naji, J. J., Dunnett, S. B., & Rosser, A. (2005) · Clinical Science · doi:10.1042/cs20050148 · Cited by 55
“Evidence from a Drosophila model of HD has shown that HDAC inhibitors halted neuronal degeneration and extended survival [ 49 ].”
BackgroundComplexity and Heterogeneity: What Drives the Ever‐changing Brain in Huntington's Disease?
Rosas, H. D., Salat, D. H., Lee, S. Y., Zaleta, A. K., Hevelone, N. D., & Hersch, S. M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.034 · Cited by 59
Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?
Bates, G. P., & Hockly, E. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000084223.82329.bb · Cited by 57
Glial AP1 is activated with aging and accelerated by traumatic brain injury
Byrns, C. N., Saikumar, J., & Bonini, N. M. (2021) · Nature Aging · doi:10.1038/s43587-021-00072-0 · Cited by 49
Structure, Activity and Function of the SETDB1 Protein Methyltransferase
Markouli, M., Strepkos, D., & Piperi, C. (2021) · Life · doi:10.3390/life11080817 · Cited by 55
“The use of HDACi helps to restore normal transcription and prevents histone deacetylation in the presence of mHTT [145,146].”
BackgroundPathogenic Mechanisms in Huntington's Disease
Jones, L., & Hughes, A. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00015-8 · Cited by 57
Gonzales, E. R., Chen, H., Munuve, R. M., Mehrani, T., Britten-Webb, J., Nadel, A., Alam, H. B., Wherry, D. C., Burris, D., & Koustova, E. (2006) · Shock · doi:10.1097/01.shk.0000209522.28120.c8 · Cited by 50
“Again, SAHA affects the acetylation levels of histones H3 and H4 (30).”
BackgroundPirooznia, S. K., & Elefant, F. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00030 · Cited by 57
Weight bearing asymmetry in standing hemiparetic patients
Pérennou, D. A. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.050468 · Cited by 59
Huntington’s disease and striatal signaling
Roze, E. F., Cahill, E., Martin, E., Bonnet, C., Vanhoutte, P., Betuing, S., & Caboche, J. (2011) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2011.00055 · Cited by 66
Altered lipid metabolism in Drosophila model of Huntington’s disease
Aditi, K., Shakarad, M. N., & Agrawal, N. (2016) · Scientific Reports · doi:10.1038/srep31411 · Cited by 49
Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?
Ziemka‐Nałęcz, M., Jaworska, J., Sypecka, J., & Zalewska, T. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly073 · Cited by 53
Abugable, A. A., Morris, J. L. M., Palminha, N. M., Zaksauskaite, R., Ray, S., & El‐Khamisy, S. F. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102669 · Cited by 58
Riester, D., Hildmann, C., & Schwienhorst, A. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-0912-1 · Cited by 54
“Similar results have been obtained in the Drosophila model (Steffan et al. 2001).”
ResultPrivacy issues on the Internet
Chung, W., & Paynter, J. (2003) · Hawaii International Conference on System Sciences (HICSS) · doi:10.1109/hicss.2002.994191 · Cited by 55
Drottar, M., Liberman, M. C., Ratan, R. R., & Roberson, D. W. (2006) · The Laryngoscope · doi:10.1097/01.mlg.0000197630.85208.36 · Cited by 50
Recent advances in Huntingtonʼs disease: implications for experimental therapeutics
Feigin, A., & Zgaljardic, D. J. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200208000-00013 · Cited by 54
The role of amyloidogenic protein oligomerization in neurodegenerative disease
Lotz, G., & Legleiter, J. (2013) · Journal of molecular medicine · doi:10.1007/s00109-013-1025-1 · Cited by 44
“acetylation [135], whereas HDAC1, a histone deacetylase, strongly decreases its acetylation.”
Chiu, S., Terpstra, K. J., Bureau, Y., Hou, J., Raheb, H., Cernvosky, Z., Badmeav, V., Copen, J., Husni, M., & Woodbury-Farina, M. (2013) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2013-0020 · Cited by 55
Besson, M.-T., Dupont, P., Fridell, Y.-W. C., & Liévens, J.-C. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq249 · Cited by 49
“Giangrande), UAS-Httex1p Q93 (57), UAS-hUCP2 (34), Mn-SOD7; OAT-Catalase5 (37) and OK107-GFP (32).”
Metadata
- Authors
- Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., Kurokawa, R., Housman, D. E., Jackson, G. R., Marsh, J. L., & Thompson, L. M.
- Affiliations
- University of California, Irvine (US)
- National Institutes of Health (US)
- Massachusetts Institute of Technology (US)
- University of California San Diego (US)
- University of California, Los Angeles (US)
- Corresponding author
- Thompson, Leslie M.
- ORCID
- Venue
- Nature
- Published
- 2001-10
- Volume
- 413
- Issue
- 6857
- Pages
- 739-743
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1643390591
- Cited by
- 1,228
- References
- 28
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 35 · 2020: 35 · 2019: 30 · 2018: 37 · 2017: 34 · 2016: 40 · 2015: 46 · 2014: 63 · 2013: 65 · 2012: 55
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Hereditary Disease Foundation
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- histone deacetylase inhibitors, polyglutamine expansion, Huntington's disease, neurodegeneration, huntingtin exon 1, CREB-binding protein, P300, PCAF, histone acetylation, histone deacetylase, Drosophila model, transcriptional dysregulation
- MeSH terms
- Huntingtin Protein, Acetylation, Acetyltransferases, Animals, Disease Models, Animal, Drosophila, Enzyme Inhibitors, Gene Expression Regulation, Glutamine, Glutathione Transferase, Histone Deacetylases, Histones, Huntington Disease, Nerve Degeneration, Nerve Tissue Proteins, Nuclear Proteins, Peptides, Repressor Proteins, Trans-Activators, PC12 Cells, Protein Structure, Tertiary, Neurodegenerative Diseases, Repetitive Sequences, Amino Acid, Saccharomyces cerevisiae Proteins, Drosophila Proteins, Animals, Genetically Modified, E1A-Associated p300 Protein, CREB-Binding Protein, Rats, Histone Acetyltransferases, Sin3 Histone Deacetylase and Corepressor Complex, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.